<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594488</url>
  </required_header>
  <id_info>
    <org_study_id>118-15</org_study_id>
    <nct_id>NCT02594488</nct_id>
  </id_info>
  <brief_title>Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction</brief_title>
  <acronym>SMART-MI</acronym>
  <official_title>Implantable Cardiac Monitors in High-risk Post-infarction Patients With Cardiac Autonomic Dysfunction and Moderately Reduced Left Ventricular Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of deaths after myocardial infarction occurs in patients with preserved left
      ventricular ejection fraction (&gt;35%) for whom no prophylactic strategies exist. Periodic
      Repolarization Dynamics (PRD) and Deceleration Capacity (DC) of heart rate are autonomic risk
      markers that identify a new high risk group of patients with LVEF 35-50% who have the same
      poor prognosis as patients with LVEF ≤35%.

      In SMART-MI, post-infarction patients with LVEF 35-50% and abnormal PRD and/or DC will be
      randomly assigned to biomonitoring-guided therapy or conventional follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) is the most common single cause of death in the industrialized
      world. Patients after myocardial infarction (MI) are at increased risk of SCD. Current
      guidelines recommend prophylactic ICD-implantation in post-MI patients with reduced left
      ventricular ejection fraction (LVEF ≤35%). However, the majority of arrhythmic deaths after
      MI occurs in patients with LVEF &gt;35% in whom no specific prophylactic strategies exist,
      indicating an important unmet medical need.

      There is a large body of evidence that presence of cardiac autonomic dysfunction after MI is
      associated with an increased susceptibility to malignant brady- and tachyarrhythmias
      eventually culminating in SCD. Periodic repolarization dynamics (PRD) and heart rate
      deceleration capacity (DC) are clinically validated autonomic risk markers that provide
      strong and independent prognostic information in post-MI patients with LVEF &gt;35%. PRD and DC
      reflect different facets of autonomic function and can therefore be used in combination to
      predict risk. Previous studies demonstrated that combined assessment of PRD and DC identifies
      a new high-risk group among post-MI patients with moderately reduced LVEF (36-50%). This new
      high-risk group has similar characteristics with respect to prognosis and patient numbers as
      the established high-risk group identified by LVEF ≤35%.

      However, the exact mechanisms leading to death in this new high-risk group need to be
      investigated in order to develop specific preventive strategies. As known from studies with
      implantable cardiac monitors (ICM) in post-MI patients with LVEF ≤40% eventual death is often
      preceded by primarily asymptomatic serious arrhythmic events. These data suggest a potential
      time frame for pre-emptive interventions in case of arrhythmic events, which could improve
      outcome.

      Therefore, SMART-MI will assess the occurrence and prognostic implications of serious
      arrhythmic events in this newly identified high-risk group by remote monitoring with ICM.
      Survivors of acute MI (&lt;40 days) and LVEF 36-50% undergo autonomic testing for presence of
      abnormal PRD and/or DC. Those with autonomic dysfunction will be randomly assigned to
      ICM-implantation or conventional follow-up. Superiority of ICMs in detection of predefined
      serious arrhythmic events will be tested based on a time-to-event analysis. A central ICM
      core lab will be implemented allowing for a response to arrhythmias within 48h. The effect of
      remote monitoring on clinical outcomes will be tested as secondary endpoints. The study will
      provide the rationale for a future guideline-relevant study testing prophylactic therapies in
      this newly identified high-risk group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of serious arrhythmic events</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of one of the following serious arrhythmic events: atrial fibrillation ≥6 min, higher degree AV-block ≥ IIb, ventricular tachycardia with a cycle length ≤320ms lasting for ≥12 sec (corresponding to 40 beats), sustained ventricular tachycardia and ventricular fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality, stroke, systemic arterial thromboembolism and unplanned hospitalizations for decompensated heart failure</measure>
    <time_frame>18 months</time_frame>
    <description>Time to one of following clinical events: death, stroke, systemic arterial thromboembolism and unplanned hospitalization for decompensated heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>18 months</time_frame>
    <description>Time to cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalizations for decompensated heart failure</measure>
    <time_frame>18 months</time_frame>
    <description>Time to unplanned hospitalizations for decompensated heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinus arrest &gt;6sec</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of sinus arrest &gt;6sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation ≥6 min</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of atrial fibrillation ≥6 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Higher degree AV-block ≥ IIb</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of higher degree AV-block ≥ IIb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-sustained ventricular tachycardia</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of ventricular tachycardia with a cycle length ≤320ms lasting for ≥12 sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained ventricular tachycardia / ventricular fibrillation</measure>
    <time_frame>18 months</time_frame>
    <description>Time to detection of sustained ventricular tachycardia / ventricular fibrillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Autonomic Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Remote monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up at the same frequency, but with no implantable cardiac monitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Reveal LINQ implantable cardiac monitor</intervention_name>
    <description>The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.</description>
    <arm_group_label>Remote monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction &lt;40 days

          -  Left ventricular ejection fraction 36-50%

          -  Presence of cardiac autonomic dysfunction by means of abnormal periodic repolarization
             dynamics and/or abnormal deceleration capacity

          -  Age 18-80 years

          -  Sinus rhythm

          -  Optimal medical therapy

        Exclusion Criteria:

          -  ICD or pacemaker indication

          -  Known paroxysmal or persistent atrial fibrillation

          -  Life expectancy &lt; 12 months

          -  Inability to comply with follow-up

          -  Pregnancy

          -  Participation in another trial that may interfere
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Kaeaeb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Axel Bauer, MD</last_name>
    <phone>+4989440076090</phone>
    <email>axel.bauer@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang Hamm, MD</last_name>
    <phone>+4989440072371</phone>
    <email>wolfgang.hamm@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe, Medizinische Klinik IV</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Schmitt, MD</last_name>
      <phone>+49 721 974</phone>
      <phone_ext>2901</phone_ext>
      <email>kardiologie@klinikum-karlsruhe.de</email>
    </contact>
    <investigator>
      <last_name>Armin Luik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik III</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meinrad P Gawaz, MD</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>8 36 88</phone_ext>
      <email>meinrad.gawaz@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Christine Meyer-Zürn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Bauer, MD</last_name>
      <phone>+4989440076090</phone>
      <email>axel.bauer@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Konstantinos D Rizas, MD</last_name>
      <phone>+4989440073068</phone>
      <email>konstantinos.rizas@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Axel Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Ludwig Laugwitz, MD</last_name>
      <phone>+49 89 4140</phone>
      <phone_ext>2350</phone_ext>
      <email>sekretariat-laugwitz@mytum.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Sinnecker, D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Meier, MD</last_name>
      <phone>0941 944-7210</phone>
      <email>Corinna.Schreiner@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Lars Meier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Herzzentrum Wuppertal, Klinik für Kardiologie</name>
      <address>
        <city>Wuppertal</city>
        <state>NRW</state>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melchior Seyfarth, MD</last_name>
      <phone>(0202) 896-57 08/10</phone>
      <email>melchior.seyfarth@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Till Köhler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Medizinische Klinik III</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Böhm, MD</last_name>
      <phone>+496841/16</phone>
      <phone_ext>21346</phone_ext>
      <email>michael.boehm@uniklinikum-saarland.de</email>
    </contact>
    <investigator>
      <last_name>Christian Ukena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtitätsklinikum der RWTH Aachen, Medizinische Klinik I</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Müller-Wieland, MD</last_name>
      <phone>+49 241 80</phone>
      <phone_ext>35227</phone_ext>
      <email>dirmueller@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Napp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin, Klinik für Kardiologie, Charite, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf Landmesser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Verena Tscholl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin, Klinik für Kardiologie, Charite, Campus Virchow Kinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkert Pieske, MD</last_name>
      <phone>+49 30 450 553</phone>
      <phone_ext>702</phone_ext>
      <email>burkert.pieske@charite.de</email>
    </contact>
    <investigator>
      <last_name>Florian Blaschke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Höhenried, Rehabilitationszentrum am Starnberger See</name>
      <address>
        <city>Bernried</city>
        <zip>82347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christa Bongarth, MD</last_name>
      <phone>+49 8158</phone>
      <phone_ext>32000</phone_ext>
      <email>christa.bongarth@hoehenried.de</email>
    </contact>
    <investigator>
      <last_name>Christa Bongarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Essen, Klinik für Kardiologie und Angiologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tienush Rassaf, MD</last_name>
      <phone>+49 201 723</phone>
      <phone_ext>4801</phone_ext>
      <email>tienush.rassaf@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Siebermair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald, Klinik für Innere Medizin B</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Felix, MD</last_name>
      <email>felix@uni-greifswald.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Busch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Klinikum für Kardiologie und Pneumologie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Zabel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Markus Zabel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Abteilung für Kardiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Heinz Kuck, MD</last_name>
      <phone>+49 40 18 18-85</phone>
      <phone_ext>23 25</phone_ext>
      <email>k.kuck@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Tobias Tönnis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Willems, MD</last_name>
      <phone>+49 40/ 7410-52438</phone>
      <email>willems@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Innere Medizin III</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Bonnemeier, MD</last_name>
      <email>hendrik.bonnemeier@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Lutz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Institute GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Hindricks, MD</last_name>
      <phone>+49 341 865</phone>
      <phone_ext>1592</phone_ext>
      <email>gerhard.hindricks@leipzig-hear.de</email>
    </contact>
    <investigator>
      <last_name>Gerhard Hindricks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik II</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele, MD</last_name>
      <phone>+49 451 / 500</phone>
      <phone_ext>2501</phone_ext>
      <email>hzl@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Roland Tilz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Kastrati, MD</last_name>
      <phone>+49 89 1218</phone>
      <phone_ext>4578</phone_ext>
      <email>kastrati@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Michael Joner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Neuperlach, Städtisches Klinikum München GmbH</name>
      <address>
        <city>München</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Mudra, MD</last_name>
      <phone>089 6794</phone>
      <phone_ext>2351</phone_ext>
      <email>kardiologie.kn@klinikum-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Harald Mudra, PI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://thebiosignals.org</url>
  </link>
  <link>
    <url>http://dzhk.de/</url>
    <description>Deutsches Zentrum für Herzkreislaufforschung</description>
  </link>
  <reference>
    <citation>Rizas KD, Nieminen T, Barthel P, Zürn CS, Kähönen M, Viik J, Lehtimäki T, Nikus K, Eick C, Greiner TO, Wendel HP, Seizer P, Schreieck J, Gawaz M, Schmidt G, Bauer A. Sympathetic activity-associated periodic repolarization dynamics predict mortality following myocardial infarction. J Clin Invest. 2014 Apr;124(4):1770-80. doi: 10.1172/JCI70085. Epub 2014 Mar 18. Erratum in: J Clin Invest. 2014 Jun 2;124(6):2808.</citation>
    <PMID>24642467</PMID>
  </reference>
  <reference>
    <citation>Bauer A, Kantelhardt JW, Barthel P, Schneider R, Mäkikallio T, Ulm K, Hnatkova K, Schömig A, Huikuri H, Bunde A, Malik M, Schmidt G. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet. 2006 May 20;367(9523):1674-81.</citation>
    <PMID>16714188</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2015</study_first_submitted>
  <study_first_submitted_qc>October 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Axel Bauer</investigator_full_name>
    <investigator_title>Prof. Dr. med. Axel Bauer</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Implantable cardiac monitor</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>ECG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

